CytomX Therapeutics Inc (FRA:6C1)
€ 0.8995 -0.1655 (-15.54%) Market Cap: 74.36 Mil Enterprise Value: -29.08 Mil PE Ratio: 6.00 PB Ratio: 0 GF Score: 56/100

Q2 2024 CytomX Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 09:00PM GMT
Release Date Price: €1.02 (-8.45%)
Operator

Good afternoon, everyone thank you for standing by and welcome to the CytomX Therapeutics second quarter 2024 financial results call. Please be advised that today's call is being recorded.

I will now hand the call over to your host for today, Chris Ogden, CytomX's Chief Financial Officer. Please go ahead.

Chris Ogden
CytomX Therapeutics Inc - Senior Vice President - Finance and Accounting

Thank you. Good afternoon and thank you for joining us. Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control.

Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligations to update any forward-looking statements whether as a result of new information, future developments, or otherwise.

Earlier this afternoon, we issued a press

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot